Sepsis-Associated EncephalopathyNCT05451537
Correlation of Formyl Peptide Receptor 1 With Sepsis-related Encephalopathy
An observational study of Sepsis-Associated Encephalopathy, run by General Hospital of Ningxia Medical University at 1 site in China.
Trial summary
The pathogenesis of sepsis-associated encephalopathy (SAE) is unclear, Formylpeptide receptor 1 (FPR1) is a cell membrane receptor that recruits leukocytes and mediates inflammatory responses after activation, but its role and mechanism in SAE are unknown. Read more about this study
- Who is it for?
- Ages 18 to 70 years
- Conditions the study is for
- Sepsis-Associated Encephalopathy
- How many people
- 100 participants
- Where
- 1 siteChina
- Study dates
- 1 Sep 2022to 29 Sep 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Severe sepsis and septic shock, Sepsis associated encephalopathy
Who may be able to join
- Inclusion criteria for participants were patients with an age of 18-70 years and an inclusion within 24 hours after the beginning of severe sepsis or septic shock according to the criteria that were established by the international guidelines for management of severe sepsis and septic shock.
Who cannot join
- Patients were excluded from the study if they had a previous diagnosis of a neuropsychiatric disease (head trauma, cerebral stroke, epilepsy, and intracranial infection), current brain disorders (hepatic encephalopathy, pulmonary encephalopathy, and severe electrolyte imbalance), concurrent hematologic diseases, malignant tumor, postcardiac arrest, or melanoma or if they were undergoing cancer chemotherapy.
Trial locations and contacts
1 site in 1 country.
China1 site
Department of Anesthesiology, General Hospital of Ningxia Medical University
Yinchuan, Ningxia, 750004
About this study
Official title: Correlation of Formyl Peptide Receptor 1 With Sepsis-related Encephalopathy: A Prospective Cohort Study
The pathogenesis of sepsis-associated encephalopathy (SAE) is unclear, Formylpeptide receptor 1 (FPR1) is a cell membrane receptor that recruits leukocytes and mediates inflammatory responses after activation, but its role and mechanism in SAE are unknown. This project intends to clarify the relationship between FPR1 activation and SAE from the clinical. The investigators enrolled 100 patients with sepsis in ICU. Patients were divided into two groups according to diagnostic criteria: SAE group and none-SAE group. Whole blood was collected. The serum FPR1 protein level was measured using a commercial enzyme-linked immunosorbent assay. After whole blood RNA was extracted, the expressions of FPR1 and a reference gene were quantified by an automated one-step Taqman RT-PCR assay. Multiple logistical regression analysis was used to identify the independent factors (including FPR1 activation) for the prediction of SAE outcomes.
Read the detailed description
Background The pathogenesis of sepsis-associated encephalopathy (SAE) is unclear, and there are no desired therapeutic methods. Formylpeptide receptor 1 (FPR1) is a cell membrane receptor that recruits leukocytes and mediates inflammatory responses after activation, but its role and mechanism in SAE are unknown. Our previous studies have shown that the expression of FPR1 in the hippocampus of septic mice is increased; FPR1 knockout reduces mortality and microglial activation. Based on this, it is hypothesized that during sepsis, FPR1 induces the migration and recruitment of neutrophils and monocytes to the brain, at the same time, FPR1 activation of microglia mediates brain inflammatory response and cell death, these factors induces or aggravates cognitive dysfunction. This project intends to clarify the relationship between FPR1 activation and SAE from the clinical. The study will provide some useful data for the mechanism study of SAE.
Methods Inclusion criteria for participants were patients with an age of 18-70 years and an inclusion within 24 hours after the beginning of severe sepsis or septic shock according to the criteria that were established by the international guidelines for management of severe sepsis and septic shock.
Patients were excluded from the study if they had a previous diagnosis of a neuropsychiatric disease (head trauma, cerebral stroke, epilepsy, and intracranial infection), current brain disorders (hepatic encephalopathy, pulmonary encephalopathy, and severe electrolyte imbalance), concurrent hematologic diseases, malignant tumor, postcardiac arrest, or melanoma or if they were undergoing cancer chemotherapy.
Demographic, clinical, and laboratory data were retrieved after intensive care unit (ICU) admission from the medical records made by two physicians. Age, gender, Acute Physiology and Chronic Health Evaluation II score (APACHE II score), Sequential Organ Failure Assessment (SOFA) score, GCS score, and infection sites were collected and determined during the first 24 hours of admission. basic laboratory tests, including blood lactate, B-type natriuretic peptide, and inflammatory markers of white blood cell count (WBC), procalcitonin (PCT), and C-reactive protein (CRP), were detected on admission. The GCS and mental status of the patients were evaluated twice a day, at eight o'clock in the morning and six o'clock in the afternoon, including SAE symptoms of somnolence, stupor, coma, confusion, disorientation, agitation, irritability, and decreased level of GCS. Sepsis-associated encephalopathy (SAE) was defined as cerebral dysfunction in the presence of severe sepsis as well as the presentation of two or more of the symptoms listed above after complete withdrawal of sedation.
Original cerebral dysfunction derived from hypoxic encephalopathy, severe hypoglycemia, intracranial hemorrhage, epilepsy relapse, acute ischemic stroke, and hyponatremia were excluded. Supportive treatments, such as the use of a ventilator, length of ICU stay, and 28-day mortality, were also included for assessment.
Blood samples were collected from patients on admission through venipuncture. the resultant serum samples were aliquoted and stored at -80°C until further analysis. The serum FPR1 protein level was measured using a commercial enzyme-linked immunosorbent assay.
Patients were divided into two groups according to diagnostic criteria: SAE group and none SAE group. Whole blood was collected. The serum FPR1 protein level was measured using a commercial enzyme-linked immunosorbent assay. After whole blood RNA was extracted, the expressions of FPR1 and a reference gene were quantified by an automated one-step Taqman RT-PCR assay.
Multiple logistical regression analysis was used to identify the independent factors for the prediction of SAE outcomes using the forward stepwise method with the likelihood ratio test. Correlations between variables were tested by the Pearson linear regression test. Receiver operating characteristics (ROC) analysis was used to qualify marker performance, and ROC curves were constructed to assess the sensitivity, specificity, and respective areas under the curves (AUCs) of the FPR1 protein performance with 95% CI. A value of P<0.05 was considered statistically significant.
The primary outcome is the comparison of FPR1 levels in patients with and without sepsis related encephalopathy. Secondary Outcome Measures: the comparison of laboratory data, inflammatory cytokines levels in patients with and without sepsis related encephalopathy.
- Conditions
- Sepsis-Associated Encephalopathy
- Medical subject headings
- Sepsis-Associated Encephalopathy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Sepsis associated encephalopathy group | Patients were diagnosed with sepsis related encephalopathy | |
| None sepsis associated encephalopathy group | Patients were not diagnosed with sepsis related encephalopathy |
What is being measured
The primary outcome is the main question the study is designed to answer.
The comparison of FPR1 levels in patients with and without sepsis related encephalopathy
The comparison of serum FPR1 protein levels (ng/ml) in patients with and without sepsis related encephalopathy
Measured: 3 days
Secondary outcomes (3)
The comparison of Inflammatory cytokines levels in patients with and without sepsis related encephalopathy
The comparison of serum IL-1β and IL-6 concentrations (ng/ml) in patients with and without sepsis related encephalopathy
Measured: 3 days
The comparison of peripheral blood leukocytes in patients with and without sepsis related encephalopathy
The comparison of peripheral blood leukocytes count in patients with and without sepsis related encephalopathy
Measured: 3 days
The comparison of S-100β levels in patients with and without sepsis related encephalopathy
The comparison of peripheral blood S-100β protein concentrations (ng/ml) in patients with and without sepsis related encephalopathy
Measured: 3 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jul 2022
- Study start1 Sep 2022 (estimated)
- Primary completion29 Sep 2025 (estimated)
- Study completion29 Sep 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Sepsis-Associated EncephalopathyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- General Hospital of Ningxia Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05451537
- Sponsor's protocol ID
- KYLL-2022-0139
- Status last verified
- Jun 2022
- First submitted
- 23 Jun 2022
- Last updated
- 11 Jul 2022
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Ma G, Ma J, Qu B, Zhang C, Zhu J, Chen Y, Ma Y, Meng X. Knockout or treatment with an antagonist of formyl peptide receptor 1 protects mice from sepsis by inhibiting inflammation. Cytokine. 2025 Mar;187:156872. doi: 10.1016/j.cyto.2025.156872. Epub 2025 Jan 28.
PubMed 39879890
Study at a glance
From the registry record, last updated by the sponsor on 11 Jul 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Correlation of Formyl Peptide Receptor 1 With Sepsis-related Encephalopathy: A Prospective Cohort Study
- ClinicalTrials.gov ID
- NCT05451537
- Acronym / sponsor ID
- KYLL-2022-0139
- Conditions
- Sepsis-Associated Encephalopathy
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- General Hospital of Ningxia Medical UniversityUniversity, hospital or other
- Study start
- 1 Sep 2022 (estimated)
- Primary completion
- 29 Sep 2025 (estimated)
- Study completion
- 29 Sep 2025 (estimated)
- First posted
- 11 Jul 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The pathogenesis of sepsis-associated encephalopathy (SAE) is unclear, Formylpeptide receptor 1 (FPR1) is a cell membrane receptor that recruits leukocytes and mediates inflammatory responses after activation, but its role and mechanism in SAE are unknown. This project intends to clarify the relationship between FPR1 activation and SAE from the clinical. The investigators enrolled 100 patients with sepsis in ICU. Patients were divided into two groups according to diagnostic criteria: SAE group and none-SAE group. Whole blood was collected. The serum FPR1 protein level was measured using a commercial enzyme-linked immunosorbent assay. After whole blood RNA was extracted, the expressions of FPR1 and a reference gene were quantified by an automated one-step Taqman RT-PCR assay. Multiple logistical regression analysis was used to identify the independent factors (including FPR1 activation) for the prediction of SAE outcomes.
Detailed description
Background The pathogenesis of sepsis-associated encephalopathy (SAE) is unclear, and there are no desired therapeutic methods. Formylpeptide receptor 1 (FPR1) is a cell membrane receptor that recruits leukocytes and mediates inflammatory responses after activation, but its role and mechanism in SAE are unknown. Our previous studies have shown that the expression of FPR1 in the hippocampus of septic mice is increased; FPR1 knockout reduces mortality and microglial activation. Based on this, it is hypothesized that during sepsis, FPR1 induces the migration and recruitment of neutrophils and monocytes to the brain, at the same time, FPR1 activation of microglia mediates brain inflammatory response and cell death, these factors induces or aggravates cognitive dysfunction. This project intends to clarify the relationship between FPR1 activation and SAE from the clinical. The study will provide some useful data for the mechanism study of SAE.
Methods Inclusion criteria for participants were patients with an age of 18-70 years and an inclusion within 24 hours after the beginning of severe sepsis or septic shock according to the criteria that were established by the international guidelines for management of severe sepsis and septic shock.
Patients were excluded from the study if they had a previous diagnosis of a neuropsychiatric disease (head trauma, cerebral stroke, epilepsy, and intracranial infection), current brain disorders (hepatic encephalopathy, pulmonary encephalopathy, and severe electrolyte imbalance), concurrent hematologic diseases, malignant tumor, postcardiac arrest, or melanoma or if they were undergoing cancer chemotherapy.
Demographic, clinical, and laboratory data were retrieved after intensive care unit (ICU) admission from the medical records made by two physicians. Age, gender, Acute Physiology and Chronic Health Evaluation II score (APACHE II score), Sequential Organ Failure Assessment (SOFA) score, GCS score, and infection sites were collected and determined during the first 24 hours of admission. basic laboratory tests, including blood lactate, B-type natriuretic peptide, and inflammatory markers of white blood cell count (WBC), procalcitonin (PCT), and C-reactive protein (CRP), were detected on admission. The GCS and mental status of the patients were evaluated twice a day, at eight o'clock in the morning and six o'clock in the afternoon, including SAE symptoms of somnolence, stupor, coma, confusion, disorientation, agitation, irritability, and decreased level of GCS. Sepsis-associated encephalopathy (SAE) was defined as cerebral dysfunction in the presence of severe sepsis as well as the presentation of two or more of the symptoms listed above after complete withdrawal of sedation.
Original cerebral dysfunction derived from hypoxic encephalopathy, severe hypoglycemia, intracranial hemorrhage, epilepsy relapse, acute ischemic stroke, and hyponatremia were excluded. Supportive treatments, such as the use of a ventilator, length of ICU stay, and 28-day mortality, were also included for assessment.
Blood samples were collected from patients on admission through venipuncture. the resultant serum samples were aliquoted and stored at -80°C until further analysis. The serum FPR1 protein level was measured using a commercial enzyme-linked immunosorbent assay.
Patients were divided into two groups according to diagnostic criteria: SAE group and none SAE group. Whole blood was collected. The serum FPR1 protein level was measured using a commercial enzyme-linked immunosorbent assay. After whole blood RNA was extracted, the expressions of FPR1 and a reference gene were quantified by an automated one-step Taqman RT-PCR assay.
Multiple logistical regression analysis was used to identify the independent factors for the prediction of SAE outcomes using the forward stepwise method with the likelihood ratio test. Correlations between variables were tested by the Pearson linear regression test. Receiver operating characteristics (ROC) analysis was used to qualify marker performance, and ROC curves were constructed to assess the sensitivity, specificity, and respective areas under the curves (AUCs) of the FPR1 protein performance with 95% CI. A value of P<0.05 was considered statistically significant.
The primary outcome is the comparison of FPR1 levels in patients with and without sepsis related encephalopathy. Secondary Outcome Measures: the comparison of laboratory data, inflammatory cytokines levels in patients with and without sepsis related encephalopathy.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Sepsis associated encephalopathy group | – | –Patients were diagnosed with sepsis related encephalopathy |
| None sepsis associated encephalopathy group | – | –Patients were not diagnosed with sepsis related encephalopathy |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Severe sepsis and septic shock, Sepsis associated encephalopathy
Key inclusion criteria (1 listed)
- Inclusion criteria for participants were patients with an age of 18-70 years and an inclusion within 24 hours after the beginning of severe sepsis or septic shock according to the criteria that were established by the international guidelines for management of severe sepsis and septic shock.
Key exclusion criteria (1 listed)
- Patients were excluded from the study if they had a previous diagnosis of a neuropsychiatric disease (head trauma, cerebral stroke, epilepsy, and intracranial infection), current brain disorders (hepatic encephalopathy, pulmonary encephalopathy, and severe electrolyte imbalance), concurrent hematologic diseases, malignant tumor, postcardiac arrest, or melanoma or if they were undergoing cancer chemotherapy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The comparison of FPR1 levels in patients with and without sepsis related encephalopathy
Time frame: 3 days
The comparison of serum FPR1 protein levels (ng/ml) in patients with and without sepsis related encephalopathy
3 secondary outcomes
The comparison of Inflammatory cytokines levels in patients with and without sepsis related encephalopathy
Time frame: 3 days
The comparison of peripheral blood leukocytes in patients with and without sepsis related encephalopathy
Time frame: 3 days
The comparison of S-100β levels in patients with and without sepsis related encephalopathy
Time frame: 3 days
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Jul 2022.
- Derived from this study: PubMed 39879890Ma G, Ma J, Qu B, Zhang C, Zhu J, Chen Y, Ma Y, Meng X. Knockout or treatment with an antagonist of formyl peptide receptor 1 protects mice from sepsis by inhibiting inflammation. Cytokine. 2025 Mar;187:156872. doi: 10.1016/j.cyto.2025.156872. Epub 2025 Jan 28.
Related trials for Sepsis-Associated Encephalopathy
Not yet recruitingObservational study
EEG Changes and Cognitive Profiles in Sepsis Patients With Different Inflammatory Phenotypes
Sepsis, Sepsis Associated Encephalopathy
Active, not recruitingObservational study
Sepsis Associated Encephalopathy (SAE) Biomarkers
Sepsis, Altered Mental Status
RecruitingObservational study
Establishment of a Cohort of Patients With Sepsis-associated Encephalopathy (SAE)
Sepsis-Associated Encephalopathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sepsis-Associated Encephalopathy, run by General Hospital of Ningxia Medical University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 11 Jul 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Gang Ma, doctor (13709519220 ext. +86, magang2671@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The comparison of FPR1 levels in patients with and without sepsis related encephalopathy (time frame: 3 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05451537, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Jul 2022.